Rocío Gómez-Cansino
Research Subjects
Rocío Gómez-Cansino has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Anahí Rodríguez-López1 shared publication
- Gerardo González de la Cruz
Cinvestav-IPN
1 shared publication - Jorge Reyes-Esparza
Universidad Autónoma del Estado de Morelos
1 shared publication - Lourdes Rodríguez-Fragoso
Univ Autonoma Del Estado de Morelos
1 shared publication - Patricia Rodríguez-Fragoso
Departamento de Física, CINVESTAV-I.P.N., Apartado Postal 14-740, 07000, Mexico, D.F., Mexico.
1 shared publication
Latest Publications
- Open Access
- 21 March 2018
- Published by IntechOpen
Interaction of Nanoparticles with Blood Components and Associated Pathophysiological Effects
Nanotechnology currently plays a pivotal role in several fields and has enabled substantial advances in a relatively short time. In biomedicine, nanomaterials can be potentially employed as a tool for early diagnosis and an innovative mode of drug delivery. Novel nanomaterials are currently widely manipulated without a full assessment of their potential health risks. It is commonly thought that nanomaterials’ first contact with the organism is through the different components of the immune system. However, if the entry route is intravenous, the first contact will be with the blood’s components (erythrocytes, platelets, white cells, plasma and complement proteins). The presence of nanomaterials within a dynamic environment such as the bloodstream can produce potential harmful effects following interaction with several blood components. The design of innovative strategies leading to the development of more hemocompatible nanomaterials is also necessary.
- 21 March 2018
- Published by IntechOpen
Open AccessInteraction of Nanoparticles with Blood Components and Associated Pathophysiological Effects
Nanotechnology currently plays a pivotal role in several fields and has enabled substantial advances in a relatively short time. In biomedicine, nanomaterials can be potentially employed as a tool for early diagnosis and an innovative mode of drug delivery. Novel nanomaterials are currently widely manipulated without a full assessment of their potential health risks. It is commonly thought that nanomaterials’ first contact with the organism is through the different components of the immune system. However, if the entry route is intravenous, the first contact will be with the blood’s components (erythrocytes, platelets, white cells, plasma and complement proteins). The presence of nanomaterials within a dynamic environment such as the bloodstream can produce potential harmful effects following interaction with several blood components. The design of innovative strategies leading to the development of more hemocompatible nanomaterials is also necessary.